ClinicalTrials.gg
RecruitingNCT05587894OPTICOVUpdated Oct 19, 2026

OPtimisation of Antiviral Therapy in Immunocompromised COVID-19 Patients: a Randomized Factorial Controlled Strategy Trial

A Phase 2 interventional study of Paxlovid 5 days and Paxlovid 10 days in COVID-19 and Immunodeficiency, sponsored by ANRS, Emerging Infectious Diseases. Recruiting at 18 sites in 3 countries. Open to participants aged 16 Years and older. Per ClinicalTrials.gov, last updated 2026-10-19.

Sponsored by ANRS, Emerging Infectious Diseases · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Apr 2023; still recruiting 3 years 6 months later.
Updated Oct 19, 2026Primary completion movedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
256
Allocation
Randomized
Ages
16 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 40 studies testing remdesivir in COVID-19 — 6 open to participants now, 9 under way, 3 of them phase 3. remdesivir · COVID-19.

Planned enrollment
22nd of 40
256 · median 283
Started
2023
the only one that year
Phase 2
6 of 40
3 open now
Registered
35th of 40
by date
Lead sponsor
1 of 40
ANRS, Emerging Infectious Diseases

Among the 40 studies testing remdesivir in COVID-19, this one is the 22nd largest by planned enrollment, is the only one that started in 2023, is one of 6 in phase 2, and was the 35th registered.

COVID-19

7,996 studies on the registry are indexed under COVID-19; 469 are open to participants now.

Browse COVID-19 studies →

Open to participants now

6 of the 40 studies testing remdesivir in COVID-19 are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 6 open studies →

About remdesivir

remdesivir: first FDA approval 2020 (VEKLURY), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 356 COVID-19 studies recruiting now, 205 (58%) set no upper age limit and 84 (24%) stop at 75 or younger; 90 take children under 18; 135 take healthy volunteers.

This study: 16 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 40 studies testing remdesivir in COVID-19, or all of them as a file.
02

Study summary

The overall purpose of the trial is to evaluate the efficacy and safety of possible combination antiviral therapy DAA (remdesivir + nirmatrelvir/r)∞ versus the reference monotherapy (nirmatrelvir/r alone) and to assess the efficacy and safety of increasing the nirmatrelvir/r course from 5- to 10 days in immunocompromised patients diagnosed with asymptomatic or mild to moderate COVID-19.

Read the detailed description

This is a randomized, controlled, factorial, superiority trial to evaluate the viral efficacy of DAA (nirmatrelvir/r) + DAA (remdesivir)∞ versus nirmatrelvir/r alone and of 5 days versus 10 days of nirmatrelvir/r in immunocompromised patients diagnosed with asymptomatic or mild to moderate COVID-19.

The primary objective is to assess whether (i) a combination antiviral therapy of two DAA (nirmatrelvir/r + remdesivir)∞ And/or (ii) an increase in nirmatrelvir/r duration from 5 to 10 days improves viral efficacy by decreasing the SARS-CoV-2 positivity rate by real time RT-PCR (CT\<32) in nasopharyngeal swabs at D10.

Patients will be eligible if they are immunocompromised, have confirmed asymptomatic SARS-CoV-2 infection or mild to moderate COVID-19, regardless of symptoms onset, provided that they have no contra-indication to any of the study drugs.

A total of 256 patients will be included in France and Switzerland.

Participants not eligible for randomisation or who refuse to participate to the trial for any reason will be proposed to be included in an exploratory non comparative cohort (maximum 97 participants).

03

Conditions studied

  • COVID-19
  • Immunodeficiency
04

Who can participate

Ages eligible
16 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Laboratory confirmed SARS-CoV-2 infection by RT-PCR or positive antigenic test (commercialized assay)
  2. Asymptomatic or mild to moderate COVID-19 (WHO progression scale \<5. Patients receiving oxygen therapy for reasons other than a pulmonary COVID-19 are eligible).
  3. ≥ 16 years of age (for patients recruited in Italy and in Norway, ≥ 18 years of age);
  4. as defined by ≥ 1 risk factors for severe COVID-19 as assessed by the FOPH list (criteria 5: diseases/treatments leading to immune suppression) or other immunosuppression criteria such as Severe immunosuppression (e.g., infection with CD4 + T cell count \<350 / µl) Neutropenia (\<1000 neutrophils / µl) ≥1 week Lymphocytopenia (\<200 lymphocytes/µl) On dialysis treatment Hereditary immunodeficiencies Intake of drugs which suppress the immune system (e.g. for a long time [an equivalent dose of prednisone >20 mg/day > 3 months], monoclonal antibodies, cytostatics, biological products, everolimus, mTOR inhibitors etc.) in the last 12 months Active cancer under cytostatics or targeted therapy known to be immunosuppressive (e.g., platinum salts, cyclophosphamide, anthracyclines, taxanes, 5-fluorouracil, gemcitabine, purine inhibitors, proteasome inhibitors) or associated with hematologic toxicity (neutropenia, lymphopenia), for example sunitinib, imatinib, regorafenib. Aggressive lymphomas (all types) Acute lymphatic leukemia Acute myeloid leukemia Acute promyelocytic leukemia T prolymphocytic leukemia Primary central nervous system lymphoma Stem cell transplantation Light chain amyloidosis Chronic lymphoid leukemia Multiple myeloma Sickle cell disease Bone marrow transplant Organ transplant Being on the waiting list for an organ transplant
  5. Willing and able to comply with study requirements and restrictions as described in the form (ICF)
  6. Enrolled in or a beneficiary of a Social Security program (State Medical Aid (AME) is not a Social Security program) or holders of health insurance (LAF for participants recruited in Norway).
  7. Participant's or its legal representative's signature of the informed consent form

Exclusion criteria

Exclusion Criteria:

  1. SARS-CoV-2 PCR ≥30 CT at screening
  2. to study drugs (active substance(s) or )
  3. Body weight \< 40 kg
  4. and/or ALT > 5 times the upper limit
  5. Cirrhosis score C
  6. Is taking or is anticipated to require any prohibited therapies*.
  7. Participation in another interventional clinical study with an compound or device, including COVID-19 therapeutics, where the study intervention is performed in the 28 days preceding the inclusion and the 10 days after the inclusion. Investigators of the different clinical studies should agree on participant's inclusion.
  8. Presence of any condition for which, in the opinion of the investigator, participation would not be in participant's best interest or that could prevent, limit, or confound the protocol-specified assessments
  9. Having received antiviral treatments against SARS-CoV-2 in the 14 days before the inclusion with exception of those having received one or two doses of nirmatrevir/r in the 24h preceding the inclusion in the study.
  10. Pregnant or breastfeeding female

    • Study SOPs based on recommendations from the Liverpool COVID-19 interactions, French Society for Pharmacology and Therapeutics (https://sfpt-fr.org/recommandations-et-publications) and French Speaking Transplantation Society will be provided to guide investigators.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
256 participants (estimated)

Study arms

  • Experimental
    Nirmatrelvir/r 5 days alone

    Drug: Paxlovid 5 days

  • Experimental
    Nirmatrelvir/r 10 days alone

    Drug: Paxlovid 10 days

  • Experimental
    Nirmatrelvir/r 5 days + remdesivir s.d

    Drug: Paxlovid 5 days · Drug: Veklury

  • Experimental
    Nirmatrelvir/r 10 days + remdesivir s.d

    Drug: Paxlovid 10 days · Drug: Veklury

Interventions

  • DrugPaxlovid 5 days

    Nirmatrelvir/r 300mg/100 mg bid will be given for 5 days, orally. Nirmatrelvir/r is a combination of two molecules: nirmatrelvir which is a protease inhibitor (against 3CL) and ritonavir which has a booster role. Nirmatrelvir/r (marketed by Pfizer under the brand name Paxlovid®) is indicated for the treatment of COVID-19 in adults who do not require supplemental oxygen and who are at increased risk for progressing to severe COVID-19.

    Also known as: Nirmatrevlir/ritonavir

  • DrugPaxlovid 10 days

    Nirmatrelvir/r 300mg/100 mg bid will be given for 10 days, orally.

    Also known as: Nirmatrevlir/ritonavir

  • DrugRemdesivirStudies of RemdesivirRemdesivir pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Remdesivir "flash", 200mg, intravenous. Remdesivir (marketed by Gilead under de brand name Veklury®) is indicated in patients with pneumonia requiring supplemental oxygen (inpatients), as well as in outpatients who are at increased risk of progressing to severe COVID-19. The mode of action characterize remdesivir as a direct-acting antiviral compound.

    Also known as: remdesivir

06

What researchers measure

Primary outcomes

  1. Percentage of patients with SARS-CoV-2 viral load (threshold cicle (Ct) <32) by real-time RT-PCR in nasopharyngeal swabs at Day 10 after treatment initiation.

    SARS-CoV-2 viral load is measured in nasopharyngeal swabs by real-time RT-PCR

    Time frame: Day 10

Secondary outcomes

  1. Percentage of patients with SARS-CoV-2 viral load (threshold cicle <32 CT) by real-time RT-PCR in nasopharyngeal swabs at Day5, Day14 and Day21 after treatment initiation

    SARS-CoV-2 viral load is measured in nasopharyngeal swabs by real-time RT-PCR

    Time frame: Day5, Day14 and Day21

  2. Percentage of patients with detectable SARS-CoV-2 viremia at Day5, Day10 and Day14

    SARS-CoV-2 viremia is measured from plasma samples by real-time RT-PCR

    Time frame: Assessed for 14 days from the date of randomisation at Day5, Day10 and Day14

  3. Decrease of SARS-CoV-2 viral load measured by copies/ml by nasopharyngeal swab at Day5, Day10, Day14, Day21 and in blood samples at Day5, Day10 and Day14 comparatively to screening

    SARS-CoV-2 viral load is measured in nasopharyngeal swabs and in blood samples by real-time RT-PCR

    Time frame: Day5, Day10, Day14, Day21

  4. Number of de novo emergence of mutations on nasopharyngeal RT-PCR at Day5, Day10, Day14 and Day21 comparatively to screening

    Emergence of mutations is measured in nasopharyngeal swabs by genotyping techniques

    Time frame: Day5, Day10, Day14 and Day21

  5. Time to first negative SARS-CoV-2 RT-PCR (CT<32) until Day90

    SARS-CoV-2 viral load is measured in nasopharyngeal swabs by real-time RT-PCR

    Time frame: Day90

  6. Absence of ability to cultivate virus from viral cultures from nasopharyngeal swabs at Day5, Day10 and Day21

    Viral culture is performed from nasopharyngeal swabs samples

    Time frame: Day5, Day10 and Day21

  7. Percentage of patients with sustained resolution or abatement of symptoms defined as a FLU-PRO-Plus score ≤1 at Day5, Day10, Day14, Day21 and Day28

    FLU-PRO-Plus score is measured via an arithmetic formula

    Time frame: Day5, Day10, Day14, Day21 and Day28

  8. All-cause hospitalization and/or death at Day28

    Outcome measured during patients medical follow-up

    Time frame: Day28

  9. Hospitalization at Day28

    Outcome measured during patients medical follow-up

    Time frame: Day28

  10. Death at Day28

    Outcome measured during patients medical follow-up

    Time frame: Day28

  11. Rate of Post-COVID19 condition at Day90 according to the WHO October 2021 definition

    Rate of Post-COVID19 condition at Day90 according to the WHO October 2021 definition: o Post COVID-19 condition occurs in individuals with a history of probable or confirmed SARS-CoV-2 infection, usually 3 months from the onset of COVID-19 with symptoms that last for at least 2 months and cannot be explained by an alternative diagnosis. Common symptoms include fatigue, shortness of breath, cognitive dysfunction but also others and generally have an impact on everyday functioning. Symptoms may be new onset following initial recovery from an acute COVID-19 episode or persist from the initial illness. Symptoms may also fluctuate or relapse over time.

    Time frame: Day 90

  12. Percentage of participants with an adverse event (AE) or serious adverse event (SAE) or AE leading to treatment discontinuation up to Day28

    Outcome measured during patients medical follow-up

    Time frame: Day 28

  13. Adherence to nirmatrelvir/r with patient-reported adherence and nirmatrelvir/r residual plasma dosage at Day5 and Day10

    Outcome measured by patient-reported adherence and drug residual dosage using dried spot (DBS)

    Time frame: Day5 and Day10

  14. Number of DDIs who led to dosage adjustment of other patient's drugs

    Outcome measured during patients medical follow-up

    Time frame: Assessed up to Day 10 from randomisation

  15. Percentage of patients with specific retreatment patients (by antiviral antiinflammatory drugs or convalescent plasma through Day90

    Outcome measured during patients medical follow-up

    Time frame: Day90

  16. To assess the phenotypic resistance (IC50 increase) against treatment for viral strains cultured from nasopharyngeal swabs

    Outcome measured in nasopharyngeal swabs by phenotyping techniques

    Time frame: Day5, Day10, Day14, Day21

  17. Immunosuppressors residual concentrations, if applicable

    Outcome measures in participants' blood samples

    Time frame: as needed

07

Study locations

18 of 18 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2023 (actual). Primary completion is estimated for Dec 2026, 44 months after the start.

Of 359 non-industry phase 2 interventional studies under COVID-19, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 18. This study's planned 44 months is above that.

Counting every sponsor, half of 583 studies reached it within 9 months; a quarter within 5 and three quarters within 16.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 19, 2026: primary completion Jun 2026 → Dec 2026 and completion Jun 2027 → Dec 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Oct 17, 2022
First posted
Oct 20, 2022
StartActual
Apr 27, 2023
Primary completionEst.
Dec 31, 2026was Jun 2026
CompletionEst.
Dec 31, 2027was Jun 2027
Last update
Oct 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Jun 30, 2026→Dec 31, 2026
Oct 19, 2026
Study completion
Jun 30, 2027→Dec 31, 2027
Oct 19, 2026
Show all 1 update
  1. Oct 19, 2026
    Primary completion Jun 30, 2026→Dec 31, 2026
    Study completion Jun 30, 2027→Dec 31, 2027
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05587894
Responsible party
Sponsor
First posted
Oct 20, 2022
Start date
Apr 27, 2023
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2027 (estimated)
Last update
Oct 19, 2026

Study contacts

Douae Ammour
Contact
douae.ammour@inserm.fr
+33782960531
Chiara Fedeli
Contact
chiara.fedeli@hug.ch
+41 (0)22 372 9817

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Remdesivir

Start the discussion